Etanercept for patients with psoriasis who did not respond or who lost their response to adalimumab or infliximab Journal Articles uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Identity
  •  
  • Additional Document Info
  •  
  • View All
  •  

abstract

  • AbstractBackgroundThere is a paucity of data on the use of etanercept in patients who have previously failed a different tumour necrosis factor (TNF) alpha antagonist.ObjectivesTo study etanercept in patients who did not achieve a satisfactory response to adalimumab or who lost their response to adalimumab or infliximab and to explore the role of anti‐adalimumab and anti‐infliximab antibodies in etanercept response.MethodsPatients with psoriasis who did not achieve a satisfactory response to adalimumab or who lost their response to adalimumab or infliximab were included. All patients received etanercept 50 mg twice a week for 12 weeks followed by 50 mg once a week for 12 more weeks. Anti‐infliximab and anti‐adalimumab antibodies were measured at baseline. The primary objective was to study the efficacy of etanercept using the proportion of patients who achieved a physician global assessment (PGA) of 0 or 1.ResultsA total of 81 patients were included. The proportion of patients who achieved a PGA of 0 or 1 after 24 weeks of etanercept was 20.0% (95% CI 4.8–35.2%) for patients who had an unsatisfactory response to adalimumab, 35.1% (95% CI 19.0–51.3%) and 35.7% (95% CI 7.0–64.4%) for patients who lost their response to adalimumab and infliximab respectively. The proportion of patients who achieved a PGA of 0 or 1 at week 24 was numerically higher for patients who had anti‐adalimumab or anti‐infliximab antibodies (36.5%) as compared to those without (17.2%; P = 0.08).ConclusionsEtanercept can be effective in patients with psoriasis who failed a previous TNF alpha antagonist.

publication date

  • August 2015